Drug Profile
Research programme: nociceptin ORL-1 modulators - UniQuest
Latest Information Update: 03 Oct 2023
Price :
$50
*
At a glance
- Originator University of Queensland
- Developer UniQuest; University of Queensland
- Class Peptides
- Mechanism of Action Nociceptin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 03 Oct 2023 Discontinued - Preclinical for Pain in Australia (unspecified route)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Pain in Australia
- 04 Aug 2016 Research programme: nociceptin ORL-1 modulators - UniQuest is available for licensing - http://uniquest.com.au/filething/get/12135/Nociceptin%20ORL-1%20Modulators%20UniQuest.pdf